Sveriges mest populära poddar
Oncology Today with Dr Neil Love
Hälsa och motionMedicin

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

1 tim 3 min•6 september 2024

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

CME information and select publications here

Fler avsnitt av Oncology Today with Dr Neil Love

Visa alla avsnitt av Oncology Today with Dr Neil Love
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•17 min
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
•58 min
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
•59 min
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
•27 min
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
•1 tim
Metastatic Bladder Cancer — Rapid Case Review Issue 4
•28 min
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
•58 min
Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•15 min

Oncology Today with Dr Neil Love med Dr. Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.